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Summary. Calcium channel  blocking agents, although effec- 
tive and widely used in the symptomatic therapy of  hyperten- 
sion and ischemic heart disease, have an uncertain effect on 
the development of  coronary atherosclerosis,  plaque rupture, 
and postrupture thrombosis.  Both nifedipine and nicardipine 
have been shown to prevent the development of  new coronary 
lesions but not the progression of  exist ing lesions in prospec- 
tive randomized angiographic studies. Verapamil,  in con- 
trast, failed to prevent the development of  new coronary le- 
sions and had no significant effect on the progression of  
exist ing lesions. Dilt iazem, although not studied in patients 
with coronary atheroscleroses,  has been shown to prevent the 
development of  post-transplant coronary vascular disease. 
Despite the beneficial effects of  nifedipine and nicardipine 
on new coronary lesion development, they have not been 
shown to reduce the incidence of  recurrent ischemic events 
or mortality in the prospective randomized studies that dem- 
onstrated their effect  on new coronary lesion development. 
A relatively new dihydropyridine calcium channel blocking 
agent, amlodipine, is hypothesized to prevent atherosclerosis 
due to its calcium channel  blocking properties as well  as by 
mechanisms independent of  its calcium channel blocking 
properties. This agent has been selected for evaluation in the 
Prospective Randomized Evaluation of  the Vascular Effects  
of  Norvasc Trial (PREVENT)  to explore whether the use of  
amlodipine over 3 years will  reduce the incidence of  early 
atherosclerotic lesions and, possibly, the progression of  ex- 
isting lesions in both the coronary and carotid arterial beds. 
Amlodipine could play an important future role in the sec- 
ondary prevention of  ischemic heart disease, but further 
study and a demonstration of  a beneficial effect on recurrent 
ischemic events is required before any final conclusions con- 
cerning its effectiveness are reached. 
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Calcium channel blockers have found wide application 
in the therapy of patients with hypertension and isch- 
emic heart disease. They are effective in lowering 
blood pressure, in relieving exertional angina pectoris 
and coronary artery spasm, and in improving survival 
in patients after infarction without left ventricular 
dysfunction or heart failure. Their role in preventing 
the development of atherosclerosis is less certain but 
critical to our understanding of their place in the ther- 
apy of both hypertension and ischemic heart disease. 
If, as suggested by the preclinical data reviewed else- 
where in this supplement, calcium channel blockers 
prevent the development and possibly the progression 
of atherosclerosis, they would have a primary role in 
treating patients with hypertension and ischemic 
heart disease. If, on the other hand, calcium channel 
blockers prove not to have a beneficial effect on the 
development of atherosclerosis, plaque rupture, or 
thrombosis after plaque rupture, their role will be lira- 
ited to the symptomatic relief of hypertension and an- 
gina pectoris. 
C l i n i c a l  S t u d i e s  
Ni fedipine  
Several studies have evaluated the effects of calcium 
channel blockers on the development and progression 
of atherosclerosis, but their results do not allow a 
clear conclusion as to their effectiveness. The study 
by Loaldi et al. [1] was the first angiographic trial 
to assess the effects of a calcium channel blocker in 
humans. This study compared the calcium channel 
blocker nifedipine with the beta-adrenergic receptor 
blocking agent propranolol and with the nitrate isosor- 
bide dinitrate. Serial angiographic studies suggested 
that patients who received nifedipine had less pro- 
gression of their atherosclerosis than those assigned 
to either propranolol or isosorbide dinitrate. Although 
relatively small, this study lent emphasis to data from 
numerous preclinical studies that had shown calcium 
plays a fundamental role in the development of athero- 
sclerosis. Its conclusions prompted further clinical in- 
vestigation into the role of calcium channel blockers 
in preventing atherosclerosis. 
Additional support for the potential role of calcium 
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channel blockers in preventing the development and/ 
or progression of atherosclerosis came from the study 
by Gottlieb et al. [2], who investigated the role of 
nifedipine (compared with placebo) in patients under- 
going coronary ar tery bypass graft surgery. Their 
prospective randomized study showed that patients 
randomized to the nifedipine group had significantly 
more coronary ar tery bypass grafts that were free of 
atherosclerosis on serial angiographic follow-up than 
did those randomized to placebo. 
These encouraging studies were followed by the 
International Nifedipine Trial on Antiatherosclerotic 
Therapy (INTACT) [3], in which 425 patients with 
angiographically proven coronary atherosclerosis 
were randomized to receive either nifedipine or pla- 
cebo. Patients were followed with repeat quantitative 
arteriography over a period of 3 years. Patients ran- 
domized to nifedipine had a significant reduction in the 
development of new atherosclerotic lesions [3]. The 
progression of existing atherosclerotic lesions, how- 
ever, was not improved. 
Nicardipine 
A similar finding (i.e., the prevention of new athero- 
sclerotic lesion development) was shown in the Mon- 
treal Heart  Institute Study (MHIS) by Waters et al. 
[4], who randomized 383 patients to nicardipine or pla- 
cebo and followed them with repeat quantitative arte- 
riography over 2 years. A significant reduction in the 
incidence of new atherosclerotic lesion formation was 
noted, but, as shown previously by Lichtlen et al. in 
the INTACT study [3], no significant effect was evi- 
dent on the progression of existing atherosclerotic le- 
sions. Data from several studies thus show beneficial 
effects of calcium channel blockers on the develop- 
ment of coronary atherosclerosis. Once the lesion is 
established, however, calcium channel blockers ap- 
pear to have relatively little effect on disease progres- 
sion. 
Verapamil 
In contrast to the other calcium channel blockers, 
verapamil failed to prevent the development of new 
coronary lesions and had no significant effect on the 
progression of existing lesions. 
Diltiazem 
Further  data on the effects of calcium channel block- 
ers on vascular disease comes from a study by 
Schroeder et al. [6]; they showed that cardiac trans- 
plant patients randomized to receive the calcium chan- 
nel blocker diltiazem had significantly less obstructive 
vascular disease than those randomized to placebo. 
Although the pathology of post-transplant vascular 
disease is somewhat different from that of athero- 
sclerosis, findings obtained in this study have impor- 
tant implications both for the therapy of the post- 
transplant patient as well as the understanding of the 
role of calcium blockers in the development of obstruc- 
tive vascular disease. 
R e c u r r e n t  I s c h e m i c  E v e n t s  
Although the data on the effectiveness of calcium 
channel blockers in preventing the development of 
coronary atherosclerosis are encouraging, it is some- 
what disappointing that in both the INTACT study 
[3] (with nifedipine) and the study by Waters et al. [4] 
(with nicardipine) the incidence of recurrent  ischemic 
events was not significantly reduced and in fact 
trended in the wrong direction: There was a trend 
towards a higher incidence of recurrent  myocardial 
infarction and death despite the reduction in the de- 
velopment of new atherosclerotic lesions. Although 
the statistical power of these studies was inadequate 
to determine the effect of calcium channel blockers on 
mortality and the follow-up was relatively short, the 
hope was that agents that were effective in pre- 
venting atherosclerosis would reduce recurrent  isch- 
emic events, as has been seen with lipid-lowering 
agents [7]. 
The failure of the dihydropyridine calcium channel 
blockers to reduce ischemic events has been noted in 
meta-analyses by Held et al. [8] and, more recently, 
by Messerli et al. [9]. These authors note that there 
is in fact an excess in reinfarction and mortality in 
patients who receive first-generation dihydropyridine 
calcium channel blockers. In the meta-analysis by 
Messerli et al. [9], the odds ratio of reinfarction on 
a dihydropyridine calcium channel blocker was 1.19 
(confidence limits, 0.92-1.53), and there was an odds 
ratio of 1.16 (confidence limits, 0.99-1.35) for mor- 
tality. 
The authors note that calcium channel blockers that 
limit heart rate (e.g., verapamil and diltiazem), in con- 
trast  to the dihydropyridine calcium channel block- 
ers, had a beneficial effect on reinfarction and mortal- 
ity, with an odds ratio of 0.79 (confidence limits, 
0.67-0.94) and an odds ratio of 0.95 (confidence lim- 
its, 0.82-1.09) for reinfarction and mortality, respec- 
tively. They counsel against the use of the dihydropyr- 
idine calcium channel blockers and recommend that 
only heart-rate-limiting calcium channel blockers be 
used in the postinfarction patient who does not toler- 
ate a beta-blocking agent, because they speculate that 
heart-rate-limiting agents may have less benefit if 
heart rate is already limited by a beta-adrenergic- 
blocking agent. 
Takenaka et al. [10] also noted an increased inci- 
dence of recurrent  infarction in 1523 patients random- 
ized to receive nifedipine, diltiazem, or other calcium 
channel blockers compared with 1029 patients who did 
not receive a calcium channel blocker (all patients 
were followed a mean of 13 months). They noted a 
4.3% incidence of reinfarction in those receiving a cal- 
cium channel blocker, compared with 2.7% in those 
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who did not (p < .5). The incidence of reinfarction 
for patients taking nifedipine was 4.7%, which was 
significantly different from the 2% incidence in non- 
treated patients (p < .05), while the difference in pa- 
tients on diltiazem and the other agents, although in- 
creased when compared with the nontreated group, 
was not statistically significant. The authors con- 
cluded that calcium channel blockers increase rein- 
farction and should not be used as routine therapy. 
The reasons for the apparent failure of the first- 
generation calcium channel blockers to reduce recur- 
rent myocardial infarction and mortality despite their 
proven effects in preventing the development of new 
atherosclerotic lesions are unclear. These agents have 
a negative inotropic effect and tend to cause catechol- 
amine release; it is postulated that catecholamine re- 
lease might predispose towards plaque rupture and 
sudden cardiac death. 
Amlodipine 
We have been interested in a relatively new dihydro- 
pyridine calcium channel blocker, amlodipine. Amlo- 
dipine binds both to dihydropyridine and nondihy- 
dropyridine receptor channels [11]. It has a longer 
duration of action than the first-generation calcium 
channel blockers [11]. It is relatively hydrophobic but 
because of its positive charge it has been suggested 
to have unique effects on lipid membranes, partially 
independent of its calcium channel blocking properties 
[12]. In a primate model, Kramsch et al. [13] have 
shown that monkeys fed an atherosclerotic diet plus 
amlodipine had significantly less anatomic evidence of 
atherosclerosis than animals fed the diet alone, de- 
spite comparable increases in serum cholesterol levels 
and low-density lipoprotein (LDL) cholesterol levels. 
They also noted that amlodipine significantly de- 
creased the levels of circulating oxidized LDL, insu- 
l!n, and triglycerides. 
They suggest that amlodipine is effective in pre- 
venting atherosclerosis by its effect in blocking cal- 
cium movement into cells as well as preventing LDL 
oxidation, and that amlodipine appears to inhibit pro- 
liferation of intimal smooth muscle cells and foam cells 
as well as preventing increases in circulating insulin 
and triglycerides. Amlodipine also has relatively little 
negative inotropic effect compared with the first- 
generation calcium channel blockers. In a study by 
Kloner et al. [14] in a model of coronary artery oc- 
clusion and reperfusion, it was found that animals 
treated with amlodipine did not have any evidence of 
a negative inotropic effect, evidenced by the absence 
of an effect of amlodipine on the ratio of change in 
ventricular pressure to change in time (dp/dt). Fur- 
ther support for the absence of a negative inotropic 
effect of amlodipine can be seen in the clinical studies 
by Packer et al. [15] of patients with heart failure, 
which documented a beneficial effect of amlodipine on 
exercise performance in patients with systolic left 
ventricular dysfunction and heart failure. In contrast 
to some of the first-generation calcium channel block- 
ers, amlodipine did not cause a release of catechol- 
amines. 
Amlodipine in prevention of coronary artery 
atherosclerosis 
Due to the favorable profile of amlodipine (includ- 
ing an absence of a negative inotropic effect, failure 
to cause a release of catecholamines, long half-life, 
positive charge with an effect on the lipid bilayer, 
antioxidant effect, lack of adverse effects on se- 
rum lipids, and excellent patient tolerability) we have 
begun a s tudy-- the Prospective Randomized Evalua- 
tion of the Vascular Effects of Norvasc Trial (PRE- 
VENT)--to determine the effects of amlodipine on 
coronary artery atherosclerosis. The details and de- 
sign of this study will be presented elsewhere, but in 
brief our primary hypothesis is that amlodipine will 
reduce the incidence of early atherosclerotic lesions 
(i.e., those with a 5-20% diameter stenosis as mea- 
sured by quantitative coronary arteriography) and, 
possibly, the progression of existing lesions in pa- 
tients evaluated by coronary arteriography for clinical 
reasons. (This effect may occur independent of amlodi- 
pine's action as a calcium channel blocker.) The pri- 
mary endpoint of this study is a change in the average 
minimal diameter of the lesions after a 3-year fol- 
low-up and a decrease in the extent of carotid athero- 
sclerosis (as assessed by B-mode ultrasonography). A 
secondary hypothesis is that amlodipine will reduce 
the rate of progression of existing coronary artery 
lesions and recurrent ischemic events. 
The simultaneous evaluation of both coronary and 
carotid arterial beds should provide unique informa- 
tion both as to the effectiveness of amlodipine as well 
as to the relationship between the progression of cor- 
onary and carotid atherosclerosis. Several current 
studies are evaluating the effect of various therapeu- 
tic agents on carotid atherosclerosis via B--mode ultra- 
sonography, with the assumption that a strategy that 
prevents carotid atherosclerosis will also prevent cor- 
onary atherosclerosis. Although this may be a reason- 
able assumption with interventions that affect serum 
lipids, it is less certain in regard to a hemodynamically 
active agent (e.g., a calcium channel blocker), which, 
because it lowers blood pressure, may affect different 
vascular beds differently or at different time courses. 
Although this study is not statistically powered to 
detect the effect  of amlodipine on total mortality or 
the incidence of myocardial infarction, data from 700 
patients followed over 3 years should provide impor- 
tant information on the combined incidence of mortal- 
ity, current myocardial infarction, stroke, and hospi- 
talization for unstable angina pectoris and heart 
failure. Data will also be analyzed to determine the 
effectiveness of amlodipine in preventing procedures 
such as percutaneous transluminal coronary anglo- 
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plasty, coronary artery bypass graft surgery, and ca- 
rotid endarterectomy. 
Future Directions 
Should the PREVENT trial demonstrate a significant 
effect on the development and/or progression of ca- 
rotid and coronary atherosclerosis, amlodipine could 
play an important role in the secondary prevention of 
ischemic heart disease. It will, however, be essential 
to demonstrate that the unique properties of amlodi- 
pine translate into a significant reduction in recurrent 
ischemic events and mortality in view of data sug- 
gesting that the first-generation dihydropyridine cal- 
cium channel blockers may have an adverse effect on 
recurrent infarction and mortality [9]. 
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